Adoke Yeka
ID: UNCST-2021-R004300
|
PLATINUM: A multi-part, multi-center PLATform study to assess the efficacy, safety, tolerability and pharmacokinetics of anti-malarial agents administered as monotherapy at multiple dose levels and/or combination therapy IN patients with Uncomplicated Plasmodium falciparum Malaria.
REFNo: HS2817ES
Part A: To assess the parasite clearance time (PCT) of oral doses of an anti- malarial agent administered as monotherapy in patients with uncomplicated
P. falciparum malaria
Part B: To assess the effect on adjusted 28-day cure rate of an anti-malarial agent administered orally as combination therapy versus the standard of care (SoC) in patients with uncomplicated P. falciparum malaria.
Part A: To assess the effect on adjusted 28-day cure rate of an anti-malarial agent administered orally as monotherapy in patients with uncomplicated
P. falciparum malaria
Part B: To assess the parasite clearance time (PCT) of oral combinations of anti-malarial agents versus SoC in patients with uncomplicated P. falciparum malaria
All parts:
To characterize PK of each anti-malarial agent administered orally as monotherapy [Part A] and/or as combination therapy [Part B] in patients with uncomplicated P. falciparum malaria
To assess the safety and tolerability of each anti-malarial agent administered orally as monotherapy [Part A] and/or as combination therapy versus SoC [Part B] in patients with uncomplicated P. falciparum malaria
|
Tororo, Tororo
Tororo, Tororo
|
Uganda |
2023-09-26 11:55:15 |
2026-09-26 |
Part A 12,pART b18 |
The study population will consist of male and female patients aged ≥18 years for Part A and aged ≥12 years for Part B. |
Novartis |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Angella Natukunda
ID:
|
DETERMINANTS OF NUTRITION STATUS AMONG ADOLESCENTS IN SELECTED SECONDARY SCHOOLS OF KANUNGU DISTRICT SOUTH WEST REGION UGANDA
REFNo: SS1812ES
Broad obective
To investigate the determinants of nutrition status among adolescents in selected secondary schools in Kanungu District South West Uganda.
Specific objectives
To assess the nutrition status of adolescents in the selected secondary schools of Kanungu District South West Region Uganda.
To determine the social demographic and economic factors influencing nutrition status of adolescents in the selected secondary schools of Kanungu District South West Region Uganda.
To determine the diet-related factors influencing nutrition status of adolescents in the selected secondary schools of Kanungu District South West Region Uganda.
To determine the level of adolescent nutrition knowledge associated with nutrition status among adolescents in the selected secondary schools of Kanungu District South West Region Uganda.
|
|
Uganda |
2023-07-14 12:34:44 |
2026-07-14 |
370 |
The study population will constitute of adolescents both male and female studying in secondary schools of Kanungu district 12 to 19 years. |
Natukunda Angella |
Social Science and Humanities |
Clinical Trial |
Degree Award |
|
Tonny Kiyimba
ID:
|
Efficacy of polyphenols from Tamarindus indica fruit juice on cardiometabolic health of patients living with HIV and elevated triglycerides: A study protocol
REFNo: HS2923ES
3. To establish dose response dynamics of long-term intake of T. indica fruit juice polyphenols on selected cardiometabolic risk markers of PLWH.,2. To assess the effect of an acute, single-dose intake of T. indica fruit juice on vascular function, lipid profile and plasma levels of procyanidin metabolites.,1. To produce and evaluate the sensory acceptability of T. indica fruit juice.,To determine the efficacy of T. indica fruit juice on selected cardiometabolic risk markers of PLWH in HIV community care model in Wakiso district, Uganda.,
|
Wakiso, Kajjansi
Wakiso, Kajjansi
|
Uganda |
2023-06-20 11:05:36 |
2026-06-20 |
240 |
Participants will be adult(30-50 years) male and female patients living with HIV (PLWH) managed under the community-based model (Community Drug Distribution Points-CDDPs) in Wakiso district, central Uganda. The district encircles Kampala, Uganda's capital city with an estimated population of over 2.9 million people. The district has the highest prevalence (10%) of HIV in Uganda. Over 3,801 PLWH are currently receiving the HIV care from CDDPs in Wakiso District. The study inclusion and exclusion criteria are presented in Table 1. |
VLIROUS |
Medical and Health Sciences |
Clinical Trial |
Degree Award |
|
Harriet Ajilong
ID: UNCST-2022-R005889
|
Assessing Vitamin D serum levels in HIV-positive adolescents 10-19 years with depression in Northern Uganda
REFNo: HS3454ES
To determine the burden of depression in HIV-positive adolescents at Gulu RRH,To assess for serum Vitamin D levels in HIV Positive adolescents 10-19 years with depressive symptoms in Gulu Regional Referral Hospital Methods,
|
Gulu, Laroo
|
Uganda |
2024-01-24 22:30:43 |
2027-01-24 |
380 participants |
HIV Positive adolescents at Gulu Regional Referral Hospital |
Child Global Research Fellowship |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Ezekiel Mupere
ID: UNCST-2023-R008637
|
Earlier prime-BOOST schedule to improve MEasles protection in high burden settings (BoostME)
REFNo: HS2883ES
Safety Objectives
1.To assess the safety and reactogenicity profile of the vaccine when given at different ages
2.To assess the number of measles infections throughout the study.
Primary Objectives
1.To compare protective measles antibody concentrations at 2.5 years of age in infants receiving an early (6 months) compared to standard (9 month) dose of MCV, and a booster dose at 18 months of age.
2.To compare protective measles antibody concentrations one month after a second dose of MCV given at 12 months (early) compared to standard (18 months), in those who received an early (6 months) first dose.
Secondary Objectives
•To describe the measles antibody concentrations one month after first dose in infants receiving an early (6 months) compared to standard (9 month) dose of MCV.
•To describe the effect of maternal antibodies on infant humoral and cellular immune response to first and second doses in children vaccinated under different schedules.
•To describe the effect of maternal HIV infection on infant antibody responses post MCV1 and MCV2 given at different schedules
•To describe the impact of different vaccination schedules on responses to the rubella component of the vaccine.
Community Objectives
To assess the effect of a measles vaccination clinical trial on public perceptions of measles immunisation
|
Kampala, Kawaala
Kampala, Kisenyi
Kampala, Komamboga
Kampala, Mulago
|
Uganda |
2023-06-23 7:46:04 |
2026-06-23 |
450 infants |
Any infant aged 6 months (23-28 weeks) at screening visit and has
not received prior vaccination against measles |
University of Oxford Research Governance, Ethics and Assurance Joint Research Office Boundary Brook House Churchill Drive Headington Oxford OX3 7GB United Kingdom, and funded by Bill and Melinda Gates Foundation. |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Conrad Muzoora Kihembe
ID: UNCST-2019-R001432
|
REDUCING MORTALITY IN ADULTS WITH ADVANCED HIV DISEASE (REVIVE)
REFNo: HS2892ES
To determine whether azithromycin is effective in reducing the incidence of new infection compared to placebo in adults with advanced HIV (CD4 ≤ 100 cells/mm3).,To determine whether azithromycin is effective in reducing mortality and hospitalisation at early and late timepoints (4weeks and 24weeks) compared to placebo in adults with advanced HIV (CD4 ≤ 100 cells/mm3).,To determine whether azithromycin is an effective and safe intervention to reduce excess mortality in adults with advanced HIV (CD4 ≤ 100 cells/mm3). ,
|
All Districts, Not applicable
|
Uganda |
2023-09-27 17:43:49 |
2026-09-27 |
8000 |
18 years and above, all sexes and all tribes |
Population Health Research Institute (PHRI) Canada |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Grace Mirembe
ID: UNCST-2022-R008850
|
RV 591 entitled “A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of an Ad26.Mos4.HIV and CH505 TF chTrimer (Env) Combination to Mimic Acute HIV Viral Replication Kinetics in Healthy Adults”
REFNo: HS2891ES
To assess the safety, reactogenicity and tolerability of two vaccination regimens: rapid dose-escalation of CH505 TF chTrimer+ALFQ and Ad26.Mos4.HIV or co-administration of CH505 TF chTrimer+ALFQ and Ad26.Mos4.HIV
|
Kampala, Central
|
Uganda |
2023-07-14 9:49:16 |
2026-07-14 |
50 |
Healthy male and female participants, aged 18 to 50 years |
The Surgeon General, Department of the Army |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Proscovia Nabunya
ID: UNCST-2019-R000970
|
Say No to Stigma-Round 2: Pilot testing the impact of visuals designed to reduce mental health stigma among primary school students in Uganda
REFNo: SS1818ES
Examine the acceptability and preliminary impact of the Say No to Stigma visual solutions on children’s mental health awareness and stigma in schools.
|
|
Uganda |
2023-07-27 20:55:02 |
2026-07-27 |
100 |
One hundred (100) students in total will be recruited for this study.
Inclusion Criteria: Children: 1) ages between 8 to 13 (primary 2 to 7) enrolled in the selected school.
Exclusion Criteria: 1) inability to comprehend study procedures or participant rights as assessed by trained staff during the informed consent process; or 2) they are unwilling or unable to commit to completing the study.
|
Washington University in St. Louis |
Social Science and Humanities |
Clinical Trial |
Non-degree Award |
|
Bernard Kikaire
ID:
|
Effect of an interactive SMS system in improving the reporting of adverse drug reactions among people living with HIV in Tanzania and Uganda: a randomized controlled trial: The REMIND ADR TRIAL
REFNo: HS2922ES
To investigate the effectiveness of SMS reminders on improving ADR reporting compared to no SMS among people living with HIV in Tanzania and Kampala Uganda.
To describe the most commonly reported ADR profiles among people living with HIV in Tanzania and Uganda.
To determine the most common routes/ methods of reporting ADR used by PLHIV.
To explore the causal relationship between the commonly reported ADRs and ART.
To improve treatment options for participants who reported ADR.
To explore the technical feasibility and acceptability of the intervention in reporting ADR among PLHIV.
|
Kampala, mulago
|
Uganda |
2023-08-08 12:42:32 |
2026-08-08 |
114 |
Age between 18 and 65
confirmed and documented HIV infection
Being on ART treatment for less than one year
Able to read and understand SMS
Able to understand and willing to sign the informed consent document
Able to read and write a text message
Have a mobile phone
|
The study is funded by Eastern Africa Consortium for Clinical Research (EACCR3) which is a network of excellence under EDCTP |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Harriet Mayanja-Kizza
ID: UNCST-2021-R013074
|
A phase 2, partially-blinded, randomised trial assessing the
safety and efficacy of TBAJ876 or bedaquiline, in combination
with pretomanid and linezolid in adult participants with newly
diagnosed, drug-sensitive, smear-positive pulmonary
tuberculosis
REFNo: HS2928ES
The objectives of the trial are to evaluate the efficacy, safety, and tolerability of TBAJ876 (3 doses) or bedaquiline in combination with pretomanid and linezolid in adult participants with newly diagnosed, smear-positive pulmonary DS-TB in comparison to the SOC
|
Kampala, Mulago
Kampala, Lubowa
|
Uganda |
2023-08-07 15:20:08 |
2026-08-07 |
The trial is planned to randomise at least 60 participants per treatment arm, for a total of at least 300 participants randomised. |
Study population should have the following characteristics:
1. Signed written informed consent prior to undertaking any trial-related procedures.
2. Participants aged 18 to 65 years, inclusive.
3. Body weight (in light clothing and no shoes) ≥35 kg.
4. Sputum positive for tubercle bacilli (at least 1+ on the IUATLD/WHO scale on smear
microscopy) at the trial laboratory.
5. DS-TB participants defined as the following:
a. Sensitive to rifampicin and isoniazid by rapid sputum-based test (see trial
Mycobacteriology Laboratory Manual) AND
b. Either newly diagnosed for TB or have a history of being untreated for at least 3
years after cure from a previous episode of TB.
6. A chest x-ray during the screening period or within 14 days of screening which in the
opinion of the investigator is compatible with pulmonary TB.
7. Be of non-childbearing potential OR using effective methods of birth control as defined
below:
Non-childbearing Potential
a. Participant is not heterosexually active or practices sexual abstinence OR
b. Female participant or male participant’s female sexual partner: bilateral
oophorectomy, bilateral tubal ligation, and/or hysterectomy or has been postmenopausal with a history of no menses for at least 12 consecutive months
OR
c. Male participant or female participant’s male sexual partner: vasectomized or
has had a bilateral orchidectomy at least 3 months prior to screening
Effective method of birth control is defined as 1 of the following:
a. Double-barrier method which can include a combination of male condom,
diaphragm, cervical cap, or female condom.
Note: Female and male condom should not be used together.
b. Combination of a barrier method with hormone-based contraceptives or an intrauterine device.
Both male and female participants must be willing to continue practicing birth control
methods and not be planning to conceive throughout treatment and for 6 months after
the last dose of IMP.
References to male or female mean “assigned male or female at birth,” respectively.
|
TB Alliance |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Flavia Matovu Kiweewa
ID: UNCST-2021-R013337
|
A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the GS-9883/Emtricitabine/Tenofovir Alafenamide (GS9883/F/TAF) Fixed Dose Combination (FDC) in HIV-1 Infected Adolescents and Children.
REFNo: HS2931ES
The primary objective of this study is to confirm the dose of B/F/TAF FDC in HIV-1 infected pediatric participants, to confirm the dose of B/F/TAF TOS in HIV-1 infected pediatric participants and to evaluate the safety and tolerability these medications.
|
Kampala,
|
Uganda |
2023-07-06 17:23:47 |
2026-07-06 |
5 |
Adolescents and children |
Gilead Sciences |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Mark Kaddumukasa
ID: UNCST-2020-R001798
|
SELF MANAGEMENT INTERVENTION FOR REDUCING EPILEPSY BURDEN AMONG UGANDANS WITH EPILEPSY
REFNo: HS2944ES
1. To assess the efficacy of SMART- U vs. eTAU via an RCT.
H1: Individuals randomized to SMART-U will have significantly improved QOL and fewer seizures compared to eTAU.
H2: Individuals randomized to SMART-U will have greater improvement in depression and functional status compared to eTAU.
2. To use short message service (SMS) delivered via mobile phone text to validate patient self-reported seizure occurrence and push epilepsy self-management messaging in a practical/accessible format.
3. To obtain input from stakeholders (patients, family and clinicians) guided by an Integrated Promotion Action on Research Implementation in Health Services (i-PARIHS) framework to help establish sustainable infrastructure that will facilitate future scale up of SMART in Uganda with epilepsy partners
|
Kampala, Mulago
Mbarara, Mbarara
|
Uganda |
2023-08-25 8:11:10 |
2026-08-25 |
188 |
Target population: all adult patients attending the neurology clinic at Mulago and Mbarara hospitals.
Accessible population: All adult patients with epilepsy on treatment attending the clinic during the study period.
Study population: All adult patients with epilepsy on treatment who will meet the inclusion criteria from all tribes attuning the study clinics.
All consecutive adult patients who came either for follow up or as new referrals with confirmed diagnosis of epilepsy were screened for the inclusion into the study.
|
NIH/ USA |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Dennis Buwembo Rogers
ID: UNCST-2021-R011765
|
QUALITY OF SELF-CARE FOR OLDER (AGED 60 YEARS AND ABOVE) PEOPLE WITH DEMENTIA IN WAKISO DISTRICT, UGANDA. CAREGIVER PERCEPTIONS, AND EFFECTS OF A PSYCHOEDUCATION INTERVENTION ON QUALITY OF SELF-CARE.
REFNo: HS2958ES
To determine the effect of a remotely delivered psychoeducation intervention for caregivers of older people with dementia on the quality of self-care.,To explore the perception, caregivers of older people with dementia have towards quality of self-care.,To measure the quality of self-care for older people with dementia in Wakiso district, Uganda.,To Improve quality of self-care provided to older people with dementia through use of a remotely delivered psychoeducation intervention of caregivers of older people with dementia in Wakiso, district Uganda.,
|
Wakiso, Kiwenda
|
Uganda |
2023-09-19 7:51:22 |
2026-09-19 |
71 |
Caregivers of older people diagnosed with dementia, 18-70 years, both female and males, all tribes as applicable |
Brain Health Training Program |
Medical and Health Sciences |
Clinical Trial |
Degree Award |
|
Nixon Niyonzima
ID: UNCST-2020-R014577
|
A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO-TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE, ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER (HeredERA)
REFNo: HS2968ES
To identify and/or evaluate biomarkers that are predictive of response to Phesgo and giredestrant (i.e., predictive biomarkers), are early surrogates of efficacy, are associated with progression to a more severe disease state (i.e., prognostic biomarkers), are associated with acquired resistance to Phesgo and giredestrant, are associated with susceptibility to developing adverse events or can lead to improved adverse event monitoring or investigation (i.e., safety biomarkers), can provide evidence of Phesgo and giredestrant activity (i.e., pharmacodynamic biomarkers), or can increase the knowledge and understanding of disease biology and drug safety,To evaluate potential effects of ADAs,To evaluate the immune response to pertuzumab, trastuzumab, and rHuPH20,To evaluate the potential relationships between Phesgo and giredestrant exposure and the safety, efficacy, immunogenicity, or biomarker endpoints.,To characterize the giredestrant, pertuzumab, and trastuzumab PK profile when given in combination,To evaluate the safety of Phesgo plus giredestrant compared with Phesgo from the participant's perspective,To evaluate health utility of participants treated with Phesgo plus giredestrant compared with Phesgo to generate utility scores for use in economic models,To evaluate effects of Phesgo plus giredestrant compared with Phesgo on work productivity and activity,To evaluate the safety of Phesgo plus giredestrant compared with Phesgo,To evaluate the efficacy of Phesgo plus giredestrant compared with Phesgo,
|
Kampala, Mulago
|
Uganda |
2023-07-14 12:43:26 |
2026-07-14 |
20 |
This study will enrol patients with locally advanced or metastatic receptor positive breast cancer above 18 years of age |
La Roche Hoffman |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Nura Izath
ID: UNCST-2022-R009201
|
Autothermo-a wearable continuous temperature measuring bracelet with a central display screen.
REFNo: HS3034ES
To assess the performance of Autothermo- a wearable continuous temperature measuring bracelet and a central display screen in comparison to the standard thermometer.,To assess the feasibility and acceptability of Autothermo among health workers and parents/caregivers of admitted neonates at Mbarara Regional Referral Hospital(MRRH).,
|
Mbarara, Kamukuzi
|
Uganda |
2024-07-22 16:57:35 |
2027-07-22 |
The sample size of the health workers: Convenient sample of 4 out of 6 health workers engaged in the management and care of newborns admitted at Neonatal Intensive Care Unit-MRRH will be enrolled in the study. These study participants who will be nurses on duty will observe the use of Autothermo, ask a few questions and document findings at the end of each shift. The remaining two nurses will be recruited as study research nurses who will enroll and use Autothermo to monitor temperatures of the admitted newborns during the study period. The sample size for parents or caregivers will be calculated basing on the Kish and Leslie where P (0.5) will be the probability of parents or caregivers who will express willingness to have their newborns’ temperatures monitored with Autothermo and q (1-p) will be the probability of those who will not express willingness to use Autothermo. The study will use a precision of 0.126 and a Z of 1.96 giving a total of 60 parents or caregivers to be recruited into the study. Taking |
Feasibility and Acceptability of Autothermo: The study will include health workers and parents or primary caregivers of newborn. Parents and caregivers who are 18 years and above will be recruited and all health workers in the Neonatal Intensive Care Unit. The parents or caregivers will be informed that the Autothermo bracelet will be removed at any time at their request.
Autothermo Performance Assessment: All neonates (0 to 28 days) admitted to the neonatal unit of MRRH during the study period will be screened for inclusion into the study.
|
Ministry of ICT and National Guidance |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Rhoda Wanyenze
ID: UNCST-2021-R013352
|
A Hybrid Implementation-Effectiveness Trial of Game Changers for Cervical Cancer Prevention (GC-CCP) in Uganda
REFNo: SS1873ES
1. Conduct a multisite RCT of the GC-CCP network-based advocacy strategy to evaluate effects on CC screening uptake, access to early-stage treatment and prevention of advanced disease among unscreened alters across urban/rural and public/private clinics,4. Evaluate the cost-effectiveness of Implementing GC-CCP to increase CC screening and low cost, early-stage treatment, and prevent advanced disease, compared to enhanced usual care.,3. Examine mediators and moderators (among index, alter and network characteristics) of intervention effects on (a) alter CC screening; and (b) engagement in CC prevention advocacy of index and alter (1st and 2nd degree) to better understand its multiplier effect on diffusion of advocacy throughout a network.,2. Use a mixed methods approach (semi-structured interviews and administrative clinic data) to examine clinic-, provider-, and client-level barriers and facilitators of GC-CCP Implementation and Sustainment.,
|
Kampala, Nsambya
Kampala, Kawempe
Buikwe, Buikwe
Kayunga, Kayunga
|
Uganda |
2023-07-13 11:13:19 |
2026-07-13 |
1400 women |
Women recently screened for Cancer of the Cervix and aged 25 years and above will be enrolled as index participants, Women who have not screened for Cancer of the Cervix but are network members of index participants will be enrolled as alter participants, Clinic leadership and providers of Cervical Cancer services will participate in qualitative interviews. |
National Institute of Mental Health |
Social Science and Humanities |
Clinical Trial |
Non-degree Award |
|
PATRICK MUSINGUZI
ID: UNCST-2023-R007731
|
UTILITY, ACCEPTABILITY AND APPLICABILITY OF A NUCLEIC ACID AMPLIFICATION TEST (NAAT) IN COMPARISON WITH SYNDROMIC APPROACH IN THE MANAGEMENT OF SEXUALLY TRANSMITTED DISEASES AT MULAGO NATIONAL REFERRAL HOSPITAL IN UGANDA.
REFNo: HS3100ES
To estimate the actual relative prevalence of causative agents of STDs in our study setting.,To evaluate the acceptability of the NAAT.,To assess the degree of concordance between actual pathogens diagnosed through the molecular test and the presumed pathogens indicated by the syndromic approach.,To evaluate whether the use of NAAT for the management of STDs improves clinical outcome and microbiological cure compared with the syndromic approach.,To evaluate whether microbiological diagnosis using NAAT improves appropriateness of therapy of STDs (as a measure of clinical usefulness) in comparison with the syndromic approach without or with limited laboratory tests currently in use.,
|
|
Uganda |
2024-01-05 9:01:56 |
2027-01-05 |
240 |
Adults aged 18 years and above presenting with signs and symptoms of STDs at the Mulago Hospital STDs clinic during the study period, who provide written consent to the participation to the study and are diagnosed with UDS, AVD and GUD. |
Italian Society of Infectious and Tropical Diseases (SIMIT) |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Joseph Matovu KB
ID: UNCST-2020-R014654
|
Enhancing communication on relationship preservation, safer conception, and pre-exposure prophylaxis (PrEP) to promote HIV testing
REFNo: HS3025ES
Conduct a pilot trial of “PrEPing Healthy Families” with intervention sites implementing the novel communication,Conduct formative research to expand a communication strategy focused on relationship preservation and safer conception into a multi-component intervention with broader reach,To leverage the growing availability of PrEP to determine if and how a communication strategy focused on relationship preservation and safer conception can increase testing and entry into treatment (ART) or prevention (PrEP) among couples in Uganda,
|
Mukono, Ntaawo ward
Mityana, Central ward
Butambala, Gombe ward
|
Uganda |
2023-08-25 8:26:15 |
2026-08-25 |
267 |
The proposed study will recruit up to 267 total participants. These participants include project advisory board members (up to 25) clients in assisted partner notification (APN) or antenatal care (ANC) programs (up to 36 for in-depth interviews [IDIs], up to 150 for exit surveys), their partners (up to 36 for IDIs), and ANC/APN providers at the intervention site (up to 20).
Participants will all be aged 18 years and above and all sexes. |
Glenn Wagner |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Stephen Okoboi
ID: UNCST-2019-R001356
|
Peer Delivered HIV/Syphilis Self-Testing with Assisted Partner Notification Services for Men who Have Sex with Men (MSM) in Uganda
REFNo: HS3021ES
Estimate the cost-effectiveness of peer-delivered HIV/syphilis self-tests and partner services compared to facility-based testing.,Conduct a pilot randomized trial to pilot test the preliminary effectiveness of peer delivered HIV/syphilis self-tests and partner services versus facility-based testing., Conduct formative research to inform implementation of peer delivered self-tests for HIV and syphilis with partner services for Ugandan MSM. ,
|
|
Uganda |
2023-10-31 19:59:00 |
2026-10-31 |
200 |
Inclusion criteria: In both arms, peers will recruit network members who are
1) aged 18 years and older,
2) Self-report of anal sexual intercourse at least once in the prior quarter
3) self-identify as MSM,
4) not tested in past 3 months or never tested for HIV or syphilis before;
5) willing to provide informed consent;
6) willing to undergo study procedures
|
National Institute of health |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Rebecca Nuwematsiko
ID: UNCST-2022-R010501
|
Effect and implementation factors of a contextually adapted short message service or phone call intervention to reduce loss to follow-up among presumptive TB patients in North Central Uganda
REFNo: HS3000ES
1.To determine the proportion of pre-diagnosis LTFU among presumptive TB patients and influencing factors in North Central Uganda (Sub-study 1).
2.To explore stakeholder’s perceptions on use of an SMS or phone call intervention to reduce LTFU among presumptive TB patients in health care facilities in North Central Uganda and contextually adapt the interventions (Sub-study 2).
3.To assess the effect of a contextually adapted SMS or phone call intervention to reduce LTFU among presumptive TB patients in health care facilities in North Central Uganda (Sub-study 3).
4.To explore factors that influence implementation of a locally adapted SMS or phone call intervention to reduce LTFU among presumptive TB patients in North Central Uganda (Sub-study 3).
5.To synthesize evidence on effectiveness of mHealth interventions to reduce LTFU in the TB presumption phase in LMICs (Sub-study 4)
|
Mukono, Mukono
Buikwe, Kawolo
Mityana, Mityana
|
Uganda |
2024-08-22 13:00:28 |
2027-08-22 |
1410 |
This will include presumptive TB patients aged 18 years and above who present to the study facilities during the study period and do not complete diagnosis on the same day of the hospital visit.
Inclusion criteria
A presumptive TB patient who is;
Aged 18 years and above
Current resident in the study district
Willing to sign informed consent
Owning a personal mobile phone (The patient should be in possession of the phone at the time of screening)
Being able to read
Those sent for GeneXpert testing
Presumed for TB within 12 hours
Patient has not completed TB diagnosis on the same day
Speaks or reads English or Luganda
|
MILEAGE4TB project hosted at Makerere University School of Public Health |
Medical and Health Sciences |
Clinical Trial |
Degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|
